Study Group: Niaspan Prescribers for Raising HDL(?)
Council Members in this Study Group: 142
Request a survey with this Study Group
Leading Experts in this Study Group
Clinical Director
NYU Medical Center
Howard Weintraub, MD, FACC, is the Clinical Director of Center for the Prevention of Cardiovascular Disease at NYU Medical Center. He has been a consultant for several organizations and has been a Cardiologist for the National Football League. Dr. Weintraub has written textbook chapters on evaluation...
Harold Bays, MD, FACPPresident and Medical Director
L-MARC Research Center
Harold Bays, MD, FACE, FACP, is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC), a metabolic clinical research facility that has conducted over 400 phase I-IV clinical trials, including studies of all marketed lipid-altering drug treatments, as well...
Hossein Ardehali, MD, PhDAssistant Professor
Feinberg School of Medicine, Northwestern University
Hossein Ardehali, MD, PhD, is an Assistant Professor of Medicine at Feinberg Cardiovascular Institute in Illinois. His specialties include lipid metabolism, preventive cardiology, electrophysiology and heart failure. Dr. Ardehali's basic science research interest is in the areas of reperfusion injury...
Owner
Joshua M. Feuer, MD
Joshua Feuer, MD, FACC, is a board certified Cardiologist in private practice in Santa Barbara, California. He also serves as a Consulting Cardiologist at Santa Barbara Cottage Hospital. Dr. Feuer specializes in aggressive preventive cardiology and cardiovascular risk assessment, and reduction. He has...
Clinical Professor of Medicine
University of California, Los Angeles
Dan Streja, MD, is a Clinical Professor of Medicine at the University of California, Los Angeles. He is Co-Director of the Lipid Clinic, the Cardiovascular Prevention Clinic and Diabetes Clinic, and the Divisions of Cardiology and Endocrinology at VA Medical Center of West Los Angeles. Dr. Streja has...
Michael Davidson, MD, FACCDirector, Preventive Cardiology
The University of Chicago
Michael Davidson, MD, FACC, is the Executive Medical Director at Radiant Research Inc. and Director of Preventive Cardiology and Atherosclerosis Research and Clinical Professor of Medicine at the University of Chicago. In addition, he is Founder, President, and Chief Executive Officer of the Chicago...
Bernard Chaitman, MDProfessor and Director
SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE
Bernard Chaitman, MD, is a Professor of Internal Medicine and Director of Cardiovascular Research at St. Louis University School of Medicine, Missouri. He is also the Director of Core ECG Laboratory. Dr. Chaitman has research interests in anti-anginal drug therapies including Ranolazine, Nicorandil,...
Samuel Butman, MDInterventional Cardiologist
Verde Valley Heart LLC
Samuel Butman, MD, is an Interventional Cardiologist at Verde Valley Medical Center. Dr. Butman is also a Clinical Associate Professor of Medicine at University Medical Center in Tucson, Arizona. He has also served as the Director of Cardiology Interventional Fellows Program and Director of Cardiac...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
The recent finding that Byetta therapy decreased mortality in the ACCORD study needs to be replicated in studies designed to address that point. Even if it is replicated and statistically significant, it probably will not be true for the widely anticipated once weekly extended formulation...
The potential market for treatment of lipids(cholesterol)continues to grow. Recent recommendations regarding potential for treatment of children as young as 8 are controversial, primarily because of the lack of data to demonstrate efficacy in terms of "hard" endpoints(i.e. mortality/MI)vs. morbidity...
More than 50% of patients have the 3 ccomponents to qualify for diagnosis of Metabolic Syndrome.Twwo of the components,Diabetes and Obesity are present in 20-25% of them and are difficult to control.Exenatide seems to provide that benefit.
As exciting as the DURATION I study results have been, Roche's GLP-1 agonist is also looking good in earlier phase trials, and there are MANY competitors in this GLP-1 realm, as well as the gliptins (oral, with similar efficacy on glucose and A1c but without the dramatic weight loss), chomping at the...
This compound may have additiional benefit in type 2 diabetic patients, especially those with the cardiometabolic syndrome.
Most Common Company Types:
- Office Based Private Practice or Clinic
- Academic Medical Center/Hospital or Clinic
- Non-Academic Community Hospital or Clinic
- Government/Military Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Owner
- Physician - Director
- Partner
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms

